Package Leaflet: Information for the User
Ropivacaína Altan 10 mg/ml solution for injection EFG
ropivacaína, hydrochloride
Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.Keep this leaflet, you may need to read it again.
Contents of the pack:
Ropivacaína Altan contains ropivacaína hydrochloride, which belongs to a group of medicines called local anesthetics of the amide type.
Ropivacaína Altan is indicated in adults and children over 12 years to anesthetize (numb) specific parts of the body. It is used to stop pain or provide pain relief. It can be used for:
Do not use Ropivacaína Altan
If you are not sure if any of the above applies to you, consult your doctor before you are given Ropivacaína Altan.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before you start using Ropivacaína Altan:
Children and adolescents
Ropivacaína Altan has not been studied in premature children.
Be careful with Ropivacaína Altan:
Using Ropivacaína Altan with other medicines
Tell your doctor if you are using, have recently used, or might use any other medicines, including those obtained without a prescription and herbal medicines. This is because Ropivacaína Altan may affect how some medicines work and some medicines may have an effect on Ropivacaína Altan.
In particular, tell your doctor if you are taking any of the following medicines:
Your doctor needs to know if you are using these medicines to be able to calculate the correct dose of Ropivacaína Altan.
Tell your doctor if you are taking any of the following medicines:
This is because your body takes longer to eliminate Ropivacaína Altan if you are taking these medicines. If you are taking any of these medicines, you should avoid prolonged use of Ropivacaína Altan.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before you are given this medicine.
Ropivacaína Altan should not be used during pregnancy and breastfeeding unless your doctor considers it essential.
It is not known if ropivacaína hydrochloride affects pregnancy or passes into breast milk.
Driving and using machines
Ropivacaína Altan may cause drowsiness and affect your reaction speed. Do not drive or use tools or machines after you have been given Ropivacaína Altan until the next day.
Ropivacaína Altan contains sodium
This medicine contains 3.03 mg of sodium (main component of cooking/table salt) in each ml. This is equivalent to 0.15% of the maximum recommended daily sodium intake for an adult.
Method of administration
Ropivacaína Altan should be administered by a doctor or, occasionally, by a nurse under the supervision of a doctor.
Dose
The dose that your doctor will administer will depend on the type of pain relief you need. It will also depend on your build, age, and physical condition.
You will be given Ropivacaína Altan as an injection. The part of the body where it will be used will depend on the reason why you are being given Ropivacaína Altan. Your doctor will administer Ropivacaína Altan in one of the following places:
When Ropivacaína Altan is administered in one of these ways, it prevents the nerves from transmitting pain messages to the brain. You will stop feeling pain, heat, or cold in the area where it is used, but you may still feel other sensations such as pressure or touch.
Your doctor will decide the best way to administer this medicine.
If you are given more Ropivacaína Altan than you should
Serious side effects as a result of receiving too much Ropivacaína Altan require special treatment, and your doctor is trained to act in these situations. The first signs that too much Ropivacaína Altan has been administered are usually:
Your doctor will stop administering Ropivacaína Altan as soon as these signs appear to reduce the risk of serious side effects. If you experience any of these symptoms or think you have received too much Ropivacaína Altan, tell your doctor immediately.
More serious side effects from receiving too much Ropivacaína Altan include speech problems, muscle spasms, tremors, convulsions, seizures, and loss of consciousness.
If you experience any of these symptoms or think you may have received too much Ropivacaína Altan, tell your doctor or healthcare staff immediately.In case of overdose or accidental ingestion, contact the Toxicology Information Service Telephone 91 562 04 20.
In case of acute toxicity, the appropriate corrective measures will be taken immediately by the healthcare staff.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Important side effects to look out for:
Sudden and potentially life-threatening allergic reactions (e.g., anaphylaxis, including anaphylactic shock) are rare and affect 1 to 10 people in every 10,000.
Possible symptoms include: sudden onset of rash, itching, or hives (urticaria); swelling of the face, lips, tongue, or other parts of the body; shortness of breath, wheezing, or difficulty breathing; and a feeling of loss of consciousness. If you think Ropivacaina Altan is causing an allergic reaction, tell your doctor immediately.
Other possible side effects:
Very common (affect more than 1 in 10 patients) |
|
Common: (affect 1 to 10 in every 100 patients) |
|
Uncommon (affect 1 to 10 in every 1,000 patients) |
|
Rare (affect 1 to 10 in every 10,000 patients) |
|
Frequency not known (cannot be estimated from the available data) |
|
Other possible side effects include:
Possible side effects observed with other local anesthetics that may also be caused by Ropivacaína Altan include:
Children
In children, the side effects are the same as in adults, except for low blood pressure, which occurs less frequently in children (affects 1 to 10 children in every 100) and feeling sick, which occurs more frequently in children (affects more than 1 child in every 10).
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not freeze.
Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month shown.
From a microbiological point of view, unless the opening method excludes the risk of microbial contamination, the product should be used immediately. If not used immediately, the storage times and conditions for use are the responsibility of the user.
Medicines should not be disposed of via wastewater or household waste. Disposal of unused medicine and all materials that have come into contact with it should be done in accordance with local regulations.
Composition of Ropivacaína Altan
Appearance of the Product and Container Content
Ropivacaína Altan is presented as a transparent and colorless injectable solution. Each container contains 5 ampoules of 10 ml.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Altan Pharmaceuticals S.A.
C/ Cólquide 6, Portal 2, 1ª Planta
Edificio Prisma.
28230 Las Rozas (Madrid) - Spain
Manufacturer
Altan Pharmaceuticals S.A.
Poligono Industrial de Bernedo s/n
01118 Bernedo (Álava), Spain
O
Altan Pharmaceuticals, S.A.
Avda. de la Constitución, 198- 199, Polígono Industrial Monte Boyal,
Casarrubios del Monte, 45950 Toledo, Spain
Date of Last Revision of this Prospectus: 06/2024
-------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Ropivacaína Altan is used in several ways:
Posology
Adults and Adolescents Over 12 Years of Age:
The Table below summarizes the recommended doses most commonly used in different types of blocks. The smallest dose required to produce an effective block should be used. Clinical experience and knowledge of the patient's clinical condition are important factors in deciding the dose.
Concentration | Volume | Dose | Onset of Action | Duration | |
mg/ml | ml | mg | minutes | hours | |
ANESTHESIA IN SURGERY | |||||
Lumbar Epidural Administration | |||||
Surgery | 10 | 15-20 | 150-200 | 10-20 | 4-6 |
The doses shown in the table are those considered necessary to produce an adequate block and should be considered as recommendations for use in adults. There are individual variations in the onset and duration of action. The figures in the "Dose" column reflect the expected average dose interval. Adequate literature should be consulted for factors affecting specific block techniques and the requirements of each patient. |
Generally, anesthesia in surgery (e.g., epidural administration) requires the use of higher concentrations and doses. For surgical procedures that require deep motor block, epidural anesthesia using the 10 mg/ml formulation is recommended. For analgesia (e.g., epidural administration in the treatment of acute pain), lower concentrations and doses are recommended.
Method of Administration
Epidural and perineural administration.
Before and during injection, careful aspiration is recommended to prevent intravascular injection. When a higher dose is to be injected, a test dose of 3-5 ml of lidocaine (lignocaine) with adrenaline (epinephrine) is advised. Accidental intravascular injection can be recognized by a temporary increase in heart rate, and accidental subarachnoid injection by signs of spinal block with apnea or hypotension.
Aspiration will be required before and during administration of the main dose, which will be injected slowly or in increasing doses, at a rate of 25-50 mg/minute, while constantly monitoring the patient's vital functions and maintaining verbal contact with them. If toxic symptoms appear, administration of the drug should be interrupted immediately.
In epidural block for surgery, single doses of up to 250 mg of ropivacaína have been well tolerated.
Concentrations above 7.5 mg/ml of Ropivacaína Altan have not been studied in cesarean section interventions.
Pediatric Patients from 0 to 12 Years of Age Inclusive
The use of Ropivacaina 7.5 and 10 mg/ml may be associated with systemic and central toxic events in children. Lower concentrations (2 mg/ml) are more appropriate for administration to this population.
The use of ropivacaína has not been documented in premature infants.
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with others.
Ropivacaína Altan does not contain preservatives and is intended for single use only. Discard any unused solution.
The solution should be inspected visually before use; do not use unless the solution is transparent and colorless and the container is intact.
The intact container should not be re-introduced into the autoclave.
Other Presentations:
Ropivacaína Altan 2 mg/ml injectable solution: 10 ml ampoules
Ropivacaína Altan 7.5 mg/ml injectable solution: 10 ml ampoules
Ropivacaína Altan 2 mg/ml solution for infusion: 100 ml bags with an extra removable overwrap
Ropivacaína Altan 2 mg/ml solution for infusion: 200 ml bags with an extra removable overwrap
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.